Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib and PD-0325901 in KRAS Mutant NSCLC and Solid Tumors
NCT02022982Phase 1Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2014
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of palbociclib and mirdametinib in non-small cell lung cancer (NSCLC) and solid tumor, sponsored by Dana-Farber Cancer Institute. Primary endpoints: Safety and tolerability at 2 Years and Maximum Tolerated Dose and Recommended Phase 2 Dose at 2 years. Started Jan 2014; status: completed.
02
Drugs
palbociclibmirdametinib
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT02022982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02022982.